Know Cancer

forgot password

Feasibility of Lymphatic Mapping of Second Echelon Lymph Nodes With Methylene Blue

18 Years
Open (Enrolling by invite only)
Breast Cancer, Melanoma

Thank you

Trial Information

Feasibility of Lymphatic Mapping of Second Echelon Lymph Nodes With Methylene Blue

Inclusion Criteria:

- Histologically confirmed primary cutaneous melanoma located on the extremity or trunk

- Patients with clinically stage I-II melanoma

- Histologically confirmed invasive ductal or lobular carcinoma

- Patient undergoing surgical treatment of breast primary and sentinel lymph node
biopsy- clinically node negative

Exclusion Criteria:

- Melanoma located on the head or neck, uveal or mucosal

- Previous surgery or radiation in or near the sentinel lymph node bopsy nodal basin

- Preoperative biopsy proven regional lymph node involvement

- Failure of lymphatic mapping with radioactive colloid

- Women who are pregnant or nursing

- Prior ipsilateral axillary surgery or radiation

- Inflammatory breast cancer

- No lymph node identified in the ipsilateral breast during pathologic review of the
mastectomy specimen

- Stage IV breast cancer

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The number of subjects in whom a secondary echelon lymph node is identified

Outcome Time Frame:

one year

Safety Issue:


Principal Investigator

James Jakub, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic


United States: Institutional Review Board

Study ID:




Start Date:

April 2013

Completion Date:

April 2014

Related Keywords:

  • Breast Cancer
  • Melanoma
  • breast cancer
  • melanoma
  • sentinel lymph node biopsy
  • lymphadenectomy
  • Breast Neoplasms
  • Melanoma



Mayo Clinic in RochesterRochester, Minnesota  55905